Bahl R, Bhandari N, Kant S, Mølbak K, Østergaard E, Bhan M K
Center for Diarrheal Disease and Nutrition Research, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Eur J Clin Nutr. 2002 Apr;56(4):321-5. doi: 10.1038/sj.ejcn.1601325.
Vitamin A supplementation to mothers in the postpartum period and to their infants at routine immunization contacts is being considered to reduce vitamin A deficiency in infancy. This study was conducted to determine the impact of maternal and infant vitamin A supplementation on antibody response to oral polio vaccine (OPV).
Randomized, double blind, placebo-controlled trial.
Mothers in the intervention group received 60 mg retinol equivalent (RE) vitamin A 3-4 weeks after delivery and their infants 7.5 mg RE with each OPV dose at 6, 10 and 14 weeks of age. The control group mothers and their infants received a placebo at each of these contacts.
Geometric mean (GM) titer of neutralizing antibodies and proportion of children with protective titer to the three polioviruses at 26 weeks of age.
Vitamin A supplementation increased the proportion of infants with protective antibody titer against poliovirus type 1 (relative risk (RR) 1.15, 95% confidence interval (CI) 1.03-1.28) and the GM antibody titer (ratio of GM 1.55, 95% CI 1.03-2.31) following immunization. The proportion of infants with protective antibody titer against poliovirus type 2 (RR 0.99, 95% CI 0.94-1.05) or type 3 (RR 1.05, 95% CI 0.96-1.15) was not significantly different in vitamin A and placebo groups. The GM antibody titer for poliovirus type 2 (ratio of GM 0.99, 95% CI 0.64-1.54) or poliovirus type 3 (ratio of GM 1.10, 95% CI 0.69-1.75) also did not differ across groups.
Vitamin A given to the mothers in the postpartum period and their infants with OPV did not interfere with the antibody response to any of the three polioviruses and enhanced the response to poliovirus type 1.
考虑在产后给母亲以及在常规免疫接种时给其婴儿补充维生素A,以减少婴儿期维生素A缺乏。开展本研究以确定母婴补充维生素A对口服脊髓灰质炎疫苗(OPV)抗体反应的影响。
随机、双盲、安慰剂对照试验。
干预组母亲在分娩后3 - 4周接受60毫克视黄醇当量(RE)的维生素A,其婴儿在6周、10周和14周龄每次口服脊髓灰质炎疫苗时接受7.5毫克视黄醇当量的维生素A。对照组母亲及其婴儿在每次接种时接受安慰剂。
26周龄时针对三种脊髓灰质炎病毒的中和抗体几何平均(GM)滴度以及具有保护性滴度的儿童比例。
补充维生素A增加了接种疫苗后对1型脊髓灰质炎病毒具有保护性抗体滴度的婴儿比例(相对危险度(RR)1.15,95%置信区间(CI)1.03 - 1.28)以及GM抗体滴度(GM比值1.55,95% CI 1.03 - 2.31)。维生素A组和安慰剂组中对2型脊髓灰质炎病毒(RR 0.99,95% CI 0.94 - 1.05)或3型脊髓灰质炎病毒(RR 1.05,95% CI 0.96 - 1.15)具有保护性抗体滴度的婴儿比例无显著差异。2型脊髓灰质炎病毒(GM比值0.99,95% CI 0.64 - 1.54)或3型脊髓灰质炎病毒(GM比值1.10,95% CI 0.69 - 1.75)的GM抗体滴度在各组间也无差异。
产后给母亲及其婴儿口服脊髓灰质炎疫苗时补充维生素A,不会干扰对三种脊髓灰质炎病毒中任何一种的抗体反应,且增强了对1型脊髓灰质炎病毒的反应。